SI3911304T1 - Formulacije tablet s prirejenim sproščanjem, ki vsebujejo inhibitorje fosfodiesteraze - Google Patents

Formulacije tablet s prirejenim sproščanjem, ki vsebujejo inhibitorje fosfodiesteraze

Info

Publication number
SI3911304T1
SI3911304T1 SI202030272T SI202030272T SI3911304T1 SI 3911304 T1 SI3911304 T1 SI 3911304T1 SI 202030272 T SI202030272 T SI 202030272T SI 202030272 T SI202030272 T SI 202030272T SI 3911304 T1 SI3911304 T1 SI 3911304T1
Authority
SI
Slovenia
Prior art keywords
formulations containing
modified release
release tablet
phosphodiesterase inhibitors
tablet formulations
Prior art date
Application number
SI202030272T
Other languages
English (en)
Inventor
Marianne Rasmussen
Karin Green Hoy
Carsten Ravn
Jari Pajander
Poul E. Bertelsen
Gitte Pommergaard Pedersen
Original Assignee
UNION therapeutics A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNION therapeutics A/S filed Critical UNION therapeutics A/S
Publication of SI3911304T1 publication Critical patent/SI3911304T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI202030272T 2019-01-15 2020-01-14 Formulacije tablet s prirejenim sproščanjem, ki vsebujejo inhibitorje fosfodiesteraze SI3911304T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19151782 2019-01-15
PCT/EP2020/050798 WO2020148271A1 (en) 2019-01-15 2020-01-14 Modified release tablet formulations containing phosphodiesterase inhibitors
EP20700712.1A EP3911304B1 (en) 2019-01-15 2020-01-14 Modified release tablet formulations containing phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
SI3911304T1 true SI3911304T1 (sl) 2023-12-29

Family

ID=65030955

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202030272T SI3911304T1 (sl) 2019-01-15 2020-01-14 Formulacije tablet s prirejenim sproščanjem, ki vsebujejo inhibitorje fosfodiesteraze

Country Status (23)

Country Link
US (1) US20210386674A1 (sl)
EP (2) EP4282414A3 (sl)
JP (1) JP2022518703A (sl)
KR (1) KR20210117300A (sl)
CN (1) CN113423389A (sl)
AU (1) AU2020208761A1 (sl)
BR (1) BR112021013675A2 (sl)
CA (1) CA3125811A1 (sl)
DK (1) DK3911304T3 (sl)
EA (1) EA202191955A1 (sl)
ES (1) ES2957495T3 (sl)
FI (1) FI3911304T3 (sl)
HR (1) HRP20231127T1 (sl)
HU (1) HUE064539T2 (sl)
IL (1) IL284815A (sl)
LT (1) LT3911304T (sl)
MX (1) MX2021008536A (sl)
PL (1) PL3911304T3 (sl)
PT (1) PT3911304T (sl)
RS (1) RS64672B1 (sl)
SG (1) SG11202107372QA (sl)
SI (1) SI3911304T1 (sl)
WO (1) WO2020148271A1 (sl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7203846B2 (ja) 2017-12-15 2023-01-13 ユニオン・セラピューティクス・アクティエセルスカブ 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
BR112023019309A2 (pt) 2021-03-22 2023-10-31 Union Therapeutics As Tratamento de hidradenite supurativa com orismilaste
US11504332B2 (en) * 2021-03-23 2022-11-22 Vk Research Associates Inc. Phosphodiesterase-4 inhibitor combinations, methods of making, and methods of use thereof
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
US20050186276A1 (en) * 2003-07-17 2005-08-25 Pfizer Inc Pharmaceutical formulations
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
LT3070091T (lt) 2010-06-24 2019-07-25 Leo Pharma A/S Benzodioksolo dariniai kaip fosfodiesterazės inhibitoriai
TW201613934A (en) 2014-06-23 2016-04-16 Leo Pharma As Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX2018007219A (es) 2015-12-18 2018-08-01 Leo Pharma As Metodos para preparacion de compuestos heterociclicos de 1,3-benzodioxol.
BR112019025028A2 (pt) 2017-06-20 2020-06-16 Leo Pharma A/S Método para preparar um composto.

Also Published As

Publication number Publication date
PT3911304T (pt) 2023-09-28
PL3911304T3 (pl) 2023-12-04
EP4282414A3 (en) 2024-02-21
US20210386674A1 (en) 2021-12-16
IL284815A (en) 2021-08-31
ES2957495T3 (es) 2024-01-19
BR112021013675A2 (pt) 2021-09-14
FI3911304T3 (fi) 2023-09-25
CN113423389A (zh) 2021-09-21
DK3911304T3 (da) 2023-10-02
RS64672B1 (sr) 2023-11-30
KR20210117300A (ko) 2021-09-28
HUE064539T2 (hu) 2024-03-28
WO2020148271A1 (en) 2020-07-23
LT3911304T (lt) 2023-11-10
SG11202107372QA (en) 2021-08-30
MX2021008536A (es) 2021-11-12
AU2020208761A1 (en) 2021-08-19
CA3125811A1 (en) 2020-07-23
JP2022518703A (ja) 2022-03-16
EA202191955A1 (ru) 2021-10-07
EP4282414A2 (en) 2023-11-29
EP3911304B1 (en) 2023-09-06
EP3911304A1 (en) 2021-11-24
HRP20231127T1 (hr) 2024-01-05

Similar Documents

Publication Publication Date Title
IL284815A (en) Modified-release tablet formulations containing phosphodiesterase inhibitors
IL280593A (en) pyrrolopyrimidine itk inhibitors
ZA201808345B (en) Capsules comprising benzylpropargylethers for use as nitrification inhibitors
EP4034094A4 (en) PHOSPHODIESTERASE INHIBITORS AND THEIR USE
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
ZA201805683B (en) Liquid urease inhibitor formulations
EP3383967A4 (en) SOLID BOILER PREAMBLE WITH CONTROLLED RELEASE
EP3793505A4 (en) QUICK RELEASE CAPSULES
IL273443A (en) Bicyclic compounds for use as RIP1 kinase inhibitors
IL276689A (en) Bampedoic acid sustained release formulations
IL282083A (en) Boron-containing compounds and their use for PDE4 inhibition
IL252901A0 (en) Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors
SG11202109781QA (en) Uses of phosphodiesterase inhibitors
IL281599A (en) TYK2 kinase inhibitors
GB2558498B (en) Novel levothyroxine formulations for oral use
GB201807845D0 (en) Kinase Inhibitors
EP3863638A4 (en) PHOSPHODIESTERASE INHIBITORS
IL282576B (en) Preparations that include domperidone
IL286942A (en) Vaginal tablet formulation
GB201914388D0 (en) Kinase inhibitors
IL291366A (en) A radiolabeled grpr antagonist for use as a therapeutic
PT3710446T (pt) Compostos úteis para inibir cdk7
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors